Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autore principale: | Paul, Pulock |
---|---|
Altri autori: | Azam,Faruque |
Natura: | Tesi |
Lingua: | English |
Pubblicazione: |
Brac University
2024
|
Soggetti: | |
Accesso online: | http://hdl.handle.net/10361/23954 |
Documenti analoghi
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
di: Rahman, Tasnim
Pubblicazione: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
di: Hoque, Ismoth Ara
Pubblicazione: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
di: Karim, Samia Binte
Pubblicazione: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
di: Flora, Sanzida Alam
Pubblicazione: (2024) -
A review on targeted therapies for lung cancer
di: Ashraf, Anushey
Pubblicazione: (2023)